(Q67905123)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1836234%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

title

Evaluation of the calcium channel-blocking agents diltiazem and verapamil for treatment of feline hypertrophic cardiomyopathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1836234%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Evaluation of the Calcium Channel-Blocking Agents Diltiazem and Verapamil for Treatment of Feline Hypertrophic Cardiomyopathy (English)

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

6 December 2022

1 reference

hypertrophic cardiomyopathy

1 reference

J. M. Bright

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1836234

6 December 2022

A. L. Golden

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1836234

6 December 2022

R. E. Gompf

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1836234

6 December 2022

M. A. Walker

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1836234

6 December 2022

R. L. Toal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1836234

6 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1836234

6 December 2022

publication date

1 September 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1836234%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

19 September 2019

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1939-1676.1991.tb03134.x

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1939-1676.1991.tb03134.x/fullpdf

6 December 2022

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Journal of Veterinary Internal Medicine

6 December 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1836234%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1836234%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1836234%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

page(s)

272-282

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1836234%20AND%20SRC:MED&resulttype=core&format=json

Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2).

19 September 2019

cites work

2

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Hypertrophic cardiomyopathy: current views on etiology, pathophysiology, and management

6 December 2022

3

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status

6 December 2022

5

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Improvement in left ventricular diastolic function during intravenous and oral diltiazem therapy in patients with hypertrophic cardiomyopathy: an echocardiographic study

6 December 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: an echocardiographic study

6 December 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

High-performance liquid chromatographic analysis of diltiazem and its metabolite in plasma

6 December 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

A general methodology for the analysis of experiments with repeated measurement of categorical data

6 December 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

6 December 2022

13

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Hypertrophic cardiomyopathy: a 1987 viewpoint

6 December 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Cardiac hypertrophy: the consequences for diastole

6 December 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil

6 December 2022

16

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy.

6 December 2022

17

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Left ventricular filling in hypertrophic cardiomyopathy. An angiographic study

6 December 2022

18

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis

6 December 2022

19

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Left ventricular diastolic function in hypertrophic cardiomyopathy: assessment by radionuclide angiography.

6 December 2022

20

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy.

6 December 2022

21

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography

6 December 2022

22

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy

6 December 2022

23

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy

6 December 2022

24

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Use of calcium channel blockers in hypertrophic cardiomyopathy.

6 December 2022

26

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy

6 December 2022

28

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Reappraisal of the effect of acute betablockade on left ventricular filling dynamics in hypertrophic obstructive cardiomyopathy*

6 December 2022

29

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Diastolic function in hypertrophic cardiomyopathy: effects of propranolol and verapamil on diastolic stiffness

6 December 2022

30

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Beta-adrenergic stimulation with isoproterenol enhances left ventricular diastolic performance in hypertrophic cardiomyopathy despite potentiation of myocardial ischemia. Comparison to rapid atrial pacing

6 December 2022

32

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Time constant of isovolumic pressure fall in the intact canine left ventricle.

6 December 2022

33

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe

6 December 2022

34

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function

6 December 2022

35

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Effects of calcium-channel blocking agents on left ventricular diastolic function in hypertrophic cardiomyopathy and in coronary artery disease

6 December 2022

36

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.

6 December 2022

37

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Effects of diltiazem on left ventricular diastolic behavior in patients with hypertrophic cardiomyopathy: evaluation with exercise pulsed Doppler echocardiography

6 December 2022

38

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy

6 December 2022

39

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Influence of verapamil therapy on left ventricular performance at rest and during exercise in hypertrophic cardiomyopathy.

6 December 2022

40

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status

6 December 2022

41

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration

6 December 2022

42

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy

6 December 2022

44

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy.

6 December 2022

45

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem

6 December 2022

46

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

The effects of calcium channel blocking agents on cardiovascular function

6 December 2022

47

1 reference

https://api.crossref.org/works/10.1111/J.1939-1676.1991.TB03134.X

6 December 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1836234%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

1 reference